The Life Sciences team advised Tessera Therapeutics in its collaboration with Serotiny to engineer programmable Gene Writer proteins. Under the terms of the agreement, Serotiny will receive an upfront payment and is eligible for certain future consideration contingent upon the collaboration achieving pre-specified performance thresholds.
The collaboration will build on Tessera’s innovations in genome engineering technologies and apply Serotiny’s high-throughput multi-domain protein screening and design expertise to further optimize Tessera’s programmable Gene Writer proteins, capable of making diverse and directed alterations to the genome.
Tessera is pioneering Gene Writing technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source and offering the potential for a new category of genetic medicines. The company was founded by Flagship Pioneering, a life sciences enterprise that conceives, resources, and develops first-in-category bioplatform companies to transform human health and sustainability.
For additional details on the collaboration, please read the press release.